Sales of the Sonablate HIFU device for non-invasive treatment for localized prostate cancer were higher than expected in 2013. SonaCare Medical, the developer of the device, reported a sales total of six Sonablate HIFU devices that year, which matches the prior year’s sales record as interest in precision guided treatment technologies for prostate cancer continued to grow at an astounding rate. Through 2013 SonaCare Medical sold Sonablate HIFU devices in 2013, spanning four countries, three separate continents and four languages.
The Sonablate 500′s unique technology has helped create the growing demand for this machine. The device has high frequency imaging as well as Neurovascular Bundle Detection (NVB) software, Tissue Change Monitoring (TCM) software and real-time imaging. The real-time imaging allows surgeons to make immediate adjustments while delivering treatment. These advancements and the ease of use for the entire device were cited by users as some of the factors that contributed to their purchase decision. A focal ablation solution, which is what the Sonablate 500 offers, gives doctors a precise treatment option with a low toxicity profile. The Sonablate is unique in that it offers the ability to treat the entire gland or just part of the gland. Demand for the device in 2014 is already strong, and one device has already been sold, according to Alex Gonzalez, Vice President of Operations for SonaCare Medical. SonaCare Medical plans to showcase the advancements they have made for the Sonablate 500 at the 29th Annual EAU Congress, scheduled for April of 2014. These advances are promising news for prostate cancer patients who are interested in treating their cancers while minimizing the risk of side effects.
However, patients do need to realize that many types of prostate cancer do not actually need to be treated. Active surveillance can be a much more effective way to manage prostate cancer that is growing slowly, without any changes to a man’s quality of life. To learn more about this option for dealing with prostate cancer, visit Dr. Bert Vorstman.